Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February

Executive Summary

Teva is seeking injunction to block generic entry after court rules four patents on the three-times-a-week dosage are invalid; analysts expect launch soon after FDA approves an ANDA, with Sandoz/Momenta generic the likely leader.


Related Content

Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Teva Catches A Break On Copaxone 40mg, But For How Long?
Pfizer Warning Letter Trips Up Sandoz/Momenta’s Expected Glatopa Launch
MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report
Teva Undertaking Strategic Review As It Searches For New CEO
Teva CEO Steps Down While An Integration Hangs In The Balance
Fate Of Copaxone 40mg Patents Depends On Courts After PTAB Rejection


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts